Tarsus Pharmaceuticals (TARS) EBIT (2019 - 2026)
Tarsus Pharmaceuticals' (TARS) quarterly EBIT came in at -$6.1 million in Q1 2026, up 76.7% year-on-year from -$3.5 million in Q1 2025, and up 23.24% quarter-over-quarter from -$8.0 million in Q4 2025.
Tarsus Pharmaceuticals (TARS) EBIT (2019 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' EBIT history runs 8 years deep, the most recent figure standing at -$6.1 million for Q1 2026.
- On a quarterly basis, EBIT rose 76.7% year-over-year to -$6.1 million in Q1 2026; TTM through Mar 2026 was -$50.8 million, a 53.45% increase from a year earlier, with the FY2025 full-year figure at -$71.0 million, up 41.14% from the prior year.
- EBIT rose to -$6.1 million in Q1 2026 per TARS's latest filing, from -$8.0 million in the prior quarter.
- Across five years, EBIT topped out at -$5.2 million in Q2 2022 and bottomed at -$44.4 million in Q4 2023.
- The 5-year median for EBIT is -$24.4 million (2024), against an average of -$23.7 million.
- Across the five-year window, EBIT tumbled 528.27% in 2023 and soared 76.7% in 2026, its largest moves.
- Year by year, EBIT stood at -$15.1 million in 2022, then plunged by 195.13% to -$44.4 million in 2023, then surged by 45.06% to -$24.4 million in 2024, then soared by 67.34% to -$8.0 million in 2025, then gained by 23.24% to -$6.1 million in 2026.
- Per Business Quant, the three latest TARS EBIT figures stand at -$6.1 million (Q1 2026), -$8.0 million (Q4 2025), and -$14.5 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Tarsus Pharmaceuticals | 2.52 Bn | 2.41 Bn | 152.66 Mn | -6.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.12 Mn |
| Dec 31, 2025 | -7.98 Mn |
| Sep 30, 2025 | -14.53 Mn |
| Jun 30, 2025 | -22.18 Mn |
| Mar 31, 2025 | -26.28 Mn |
| Dec 31, 2024 | -24.42 Mn |
| Sep 30, 2024 | -25.16 Mn |
| Jun 30, 2024 | -33.30 Mn |
| Mar 31, 2024 | -37.68 Mn |
| Dec 31, 2023 | -44.45 Mn |
| Sep 30, 2023 | -40.94 Mn |
| Jun 30, 2023 | -32.82 Mn |
| Mar 31, 2023 | -24.95 Mn |
| Dec 31, 2022 | -15.06 Mn |
| Sep 30, 2022 | -22.91 Mn |
| Jun 30, 2022 | -5.22 Mn |
| Mar 31, 2022 | -19.52 Mn |
| Dec 31, 2021 | -14.45 Mn |
| Sep 30, 2021 | -15.71 Mn |
| Jun 30, 2021 | 7.28 Mn |